A rationale for monoamine oxidase inhibition as neuroprotective therapy for parkinson's disease

Keyphrases

• Parkinson's Disease 100%
• Patients with Parkinson's Disease 100%
• Substantia Nigra 100%
• Monoamine Oxidase Inhibitors 100%
• Neuroprotective Therapy 100%
• Dopamine 66%
• Oxidant Stress 66%
• Free Radicals 66%
• Glutathione 33%
• Disability 33%
• Metabolism 33%
• Lipid Peroxidation 33%
• Oxidative Metabolism 33%
• Monoamine Oxidase A (MAO-A) 33%
• Untreated Patients 33%
• Selective Inhibitor 33%
• Dopamine Neurons 33%
• Selegiline 33%
• Neuroprotective Effect 33%
• Peroxide 33%
• Hydroxyl Radical 33%
• Early Parkinson's Disease 33%
• Iron Accumulation 33%
• Postmortem Study 33%
• Natural Progression 33%
• Antioxidant Therapy 33%
• Neuromelanin 33%
• Monoamine Oxidase B Inhibitors 33%
• Aluminum Accumulation 33%
• Neuromelanin Granules 33%

Medicine and Dentistry

• Parkinson's Disease 100%
• Neuroprotective Agent 100%
• Monoamine Oxidase Inhibitor 100%
• Iron 66%
• Substantia nigra 50%
• Oxidative Stress 33%
• Amine Oxidase (Flavin Containing) 33%
• Neuromelanin 33%
• Radical (Chemistry) 33%
• Glutathione 16%
• Aerobic Metabolism 16%
• Antioxidant 16%
• Lipid Peroxidation 16%
• Selegiline 16%
• Hydroxyl Radical 16%

Neuroscience

• Parkinson's Disease 100%
• Neuroprotective Agent 100%
• Monoamine Oxidase Inhibitor 100%
• Substantia nigra 50%
• Free Radical 50%
• Oxidative Stress 33%
• Metabolic Pathway 33%
• Monoamine Oxidase 33%
• Neuromelanin 33%
• Monoamine Oxidase A 33%
• Glutathione 16%
• Antioxidant 16%
• Selegiline 16%
• Lipid Peroxidation 16%